CN101621991A - 降钙素的口服施用 - Google Patents

降钙素的口服施用 Download PDF

Info

Publication number
CN101621991A
CN101621991A CN200880006790A CN200880006790A CN101621991A CN 101621991 A CN101621991 A CN 101621991A CN 200880006790 A CN200880006790 A CN 200880006790A CN 200880006790 A CN200880006790 A CN 200880006790A CN 101621991 A CN101621991 A CN 101621991A
Authority
CN
China
Prior art keywords
amount
calcitonin
minutes
liquid
peptide drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880006790A
Other languages
English (en)
Chinese (zh)
Inventor
Y·乔希
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to CN201710436918.4A priority Critical patent/CN107050433A/zh
Publication of CN101621991A publication Critical patent/CN101621991A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
CN200880006790A 2007-03-02 2008-02-29 降钙素的口服施用 Pending CN101621991A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710436918.4A CN107050433A (zh) 2007-03-02 2008-02-29 降钙素的口服施用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89259407P 2007-03-02 2007-03-02
US60/892,594 2007-03-02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710436918.4A Division CN107050433A (zh) 2007-03-02 2008-02-29 降钙素的口服施用

Publications (1)

Publication Number Publication Date
CN101621991A true CN101621991A (zh) 2010-01-06

Family

ID=39496395

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200880006790A Pending CN101621991A (zh) 2007-03-02 2008-02-29 降钙素的口服施用
CN201710436918.4A Pending CN107050433A (zh) 2007-03-02 2008-02-29 降钙素的口服施用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710436918.4A Pending CN107050433A (zh) 2007-03-02 2008-02-29 降钙素的口服施用

Country Status (16)

Country Link
US (1) US8410052B2 (https=)
EP (1) EP2131810B1 (https=)
JP (1) JP5249246B2 (https=)
KR (2) KR20150091536A (https=)
CN (2) CN101621991A (https=)
AT (1) ATE507818T1 (https=)
AU (1) AU2008223108B2 (https=)
BR (1) BRPI0808517A2 (https=)
CA (1) CA2679782C (https=)
DE (1) DE602008006700D1 (https=)
ES (1) ES2365648T3 (https=)
MX (1) MX2009009243A (https=)
PL (1) PL2131810T3 (https=)
PT (1) PT2131810E (https=)
RU (2) RU2009136303A (https=)
WO (1) WO2008109385A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104487056A (zh) * 2012-06-20 2015-04-01 诺和诺德A/S（股份有限公司） 包含肽和递送剂的片剂制剂
CN104961687A (zh) * 2015-06-03 2015-10-07 苏州维泰生物技术有限公司 1,2-二嗪衍生物及其制剂、用途

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2651398T1 (en) 2010-12-16 2018-04-30 Novo Nordisk A/S SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
PL2696687T3 (pl) 2011-04-12 2017-06-30 Novo Nordisk A/S Pochodne podwójnie acylowanej GLP-1
EP2758057B1 (en) * 2011-09-22 2017-05-31 Exelixis, Inc. Method for treating osteoporosis
HRP20181447T1 (hr) 2012-03-22 2018-11-02 Novo Nordisk A/S Pripravci glp-1 peptida i njihova priprava
PT2827845T (pt) 2012-03-22 2019-03-29 Novo Nordisk As Composições compreendendo um agente de entrega e sua preparação
ES2965469T3 (es) 2012-03-22 2024-04-15 Novo Nordisk As Composiciones que comprenden un agente de suministro y preparación de estas
KR102272671B1 (ko) 2013-05-02 2021-07-06 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
JP6898518B2 (ja) 2018-02-02 2021-07-07 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
IL297415A (en) * 2020-04-22 2022-12-01 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Active phenolate salt complex

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629020A (en) * 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
WO2000059480A1 (en) 1999-04-05 2000-10-12 Emisphere Technologies, Inc. Lyophilized solid dosage forms and methods of making
ES2235854T3 (es) * 1999-04-05 2005-07-16 Emisphere Technologies, Inc. Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos.
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
KR20040030120A (ko) * 2001-08-17 2004-04-08 노파르티스 아게 부갑상선 호르몬 단편의 경구 전달제로서의 5-ｃｎａｃ
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
TWI307279B (en) 2002-08-01 2009-03-11 Novartis Ag Oral administration of calcitonin
ES2398237T3 (es) * 2003-07-23 2013-03-14 Novartis Ag Uso de calcitonina en osteoartritis

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104487056A (zh) * 2012-06-20 2015-04-01 诺和诺德A/S（股份有限公司） 包含肽和递送剂的片剂制剂
CN104961687A (zh) * 2015-06-03 2015-10-07 苏州维泰生物技术有限公司 1,2-二嗪衍生物及其制剂、用途
CN104961687B (zh) * 2015-06-03 2017-07-25 苏州维泰生物技术有限公司 1,2‑二嗪衍生物及其制剂、用途

Also Published As

Publication number Publication date
AU2008223108A2 (en) 2009-09-10
AU2008223108A1 (en) 2008-09-12
MX2009009243A (es) 2009-09-08
US8410052B2 (en) 2013-04-02
DE602008006700D1 (https=) 2011-06-16
RU2009136303A (ru) 2011-04-10
RU2013150659A (ru) 2015-05-20
WO2008109385A3 (en) 2009-04-09
CA2679782C (en) 2015-02-17
EP2131810B1 (en) 2011-05-04
WO2008109385A2 (en) 2008-09-12
BRPI0808517A2 (pt) 2014-08-19
US20100210526A1 (en) 2010-08-19
ATE507818T1 (de) 2011-05-15
CA2679782A1 (en) 2008-09-12
KR20150091536A (ko) 2015-08-11
PL2131810T3 (pl) 2011-09-30
EP2131810A2 (en) 2009-12-16
CN107050433A (zh) 2017-08-18
JP2010520221A (ja) 2010-06-10
ES2365648T3 (es) 2011-10-07
AU2008223108B2 (en) 2013-10-10
KR20090116772A (ko) 2009-11-11
KR101564114B1 (ko) 2015-10-28
JP5249246B2 (ja) 2013-07-31
PT2131810E (pt) 2011-08-03

Similar Documents

Publication Publication Date Title
CN101621991A (zh) 降钙素的口服施用
RU2287999C2 (ru) Фармацевтические композиции для перорального введения фармакологически действующих веществ
US7569539B2 (en) Oral administration of calcitonin
RU2493868C2 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ чГР, ДЛЯ ПЕРОРАЛЬНОГО ВВЕДЕНИЯ
AU2005202705B2 (en) Pharmaceutical compositions for the oral delivery of pharmacologically active agents

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20100106